Wellbutrin Tablet, Extended Release
NDC Package 0187-0730-07
Package Information
Wellbutrin (bupropion hydrochloride) tablets is a medication used to treat depression. This formulation utilizes a tablet, extended release delivery system. Marketed by Bausch Health Us Llc, this product is identified by NDC 0187-0730 and is authorized under FDA application NDA021515.
Identification & Billing
- RxCUI: 993541 - buPROPion HCl 150 MG 24HR Extended Release Oral Tablet
- RxCUI: 993541 - 24 HR bupropion hydrochloride 150 MG Extended Release Oral Tablet
- RxCUI: 993541 - bupropion HCl XL 150 MG 24 HR Extended Release Oral Tablet
- RxCUI: 993545 - Wellbutrin XL 150 MG 24HR Extended Release Oral Tablet
- RxCUI: 993545 - 24 HR bupropion hydrochloride 150 MG Extended Release Oral Tablet [Wellbutrin]
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 0187 - Bausch Health Us Llc
- 0187-0730 - Wellbutrin
- 0187-0730-07 - 7 TABLET, EXTENDED RELEASE in 1 BOTTLE
- 0187-0730 - Wellbutrin
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Other Available Packages
The following commercial packages are registered under the same Product NDC (0187-0730). Click a package code to view its specific billing and regulatory data.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 0187-0730-07 identifies a specific commercial package of 7 tablet, extended release in 1 bottle of Wellbutrin XL, a human prescription drug labeled by Bausch Health Us Llc. This tablet, extended release is formulated for oral use and contains bupropion hydrochloride as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Bausch Health Us Llc on August 29, 2003. The current certification is valid through December 31, 2027.
What are the primary indications for this medication?
This medication is used to treat depression. It may also be used to prevent seasonal affective disorder (SAD), a type of depression that occurs each year at the same time (for example, during winter). This medication can improve your mood and feelings of well-being. It may work by restoring the balance of certain natural substances (dopamine, norepinephrine) in the brain.
How is this Bausch Health Us Llc product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 00187073007. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 7 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Labeler segment to maintain the 5-4-2 structure.